Non–small cell lung carcinoma (NSCLC) patients with BRAF V600E–mutated tumors respond to targeted therapy. Testing for BRAF V600E is commonly performed with molecular methods; however, a mutation‐specific VE1 antibody clone… Click to show full abstract
Non–small cell lung carcinoma (NSCLC) patients with BRAF V600E–mutated tumors respond to targeted therapy. Testing for BRAF V600E is commonly performed with molecular methods; however, a mutation‐specific VE1 antibody clone can provide an alternative testing option using immunohistochemistry (IHC) for practices using single‐gene testing and in situations when the specimen is inadequate for molecular testing. This study evaluates the usefulness of VE1 IHC in screening for BRAF V600E mutations in NSCLC cytology specimens.
Journal Title: Cancer Cytopathology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!